参考文献: [1]https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453 [2] Li SS, Ma J, Wong AS.Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.J Gynecol Oncol.2018 Mar;29(2):e32. [3] Elfaki ...
2021 Ovarian Cancer Presented with support from: Available online at NCCN.org/patients Ü Ovarian Cancer Its easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options likely to have the best results 9 ...
版权归©2021NationalComprehensiveCancerNetwork,Inc公司所有。NCCNGuidelinesVersion2.2021卵巢癌NCCN卵巢癌指南版本1.2021从版本2.2020更新为:OVC考文献:►Ray-CoquardI,PautierP,PignataS,etal.Olaparibplusbevacizumabasfirst-linemaintenanceinovariancancer.NEnglJMed2019;381:2416-.►Gonzalez-MartinA,PothuriB,VergoteI,...
2021.V1+NCCN临床实践指南:卵巢癌、输卵管癌、原发性腹膜癌.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2021 — February 26, 2021 NCCN.org
版权归©2021NationalComprehensiveCancerNetwork,Inc公司所有。 NCCN指南索引 NCCN Guidelines Version2.2021 目录 卵巢癌 讨论 肿瘤治疗新技术新方法日新月异,瞬间手里的资料已被更新或再版。“单 肿瘤医生同行互帮互助群内利用AI技术,24小时在线自动派发 打独斗”的时代已经过去,靠个人去收集最新资料,着实困难。为了...
NCCNClinicalPracticeGuidelinesinOncologyNCCN肿瘤学临床实践指南(NCCNGuidelines指南?) 子宫肿瘤UterineNeoplasms 版本3.2021年-2021年6月3日2021—June03,2021 NCCN.org NCCN患者使用指南GuidelinesforPatients?available用于at /patients Continu e Version3.2021,06/03/21?2021NationalComprehensiveCancerNetwork(NCCN),All...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ova...
1.子宫内膜癌分子检测中国专家共识(2021年版) 2.中国家族遗传性肿瘤临床诊疗专家共识(2021 年版)—家族遗传性卵巢癌 3.NCCN Guidelines Version 1.2022 Cervical Cancer. 4.NCCN Guidelines Version 1.2022 Endometrial Carcinoma. 5.NCCN Guidelines Version 5.2022 Ovarian Cancer Continue Including Fallopian Tube Cancer...
Reference 2 added: Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. 原文共享 相关链接 循环肿瘤基因指导晚期乳腺癌靶向治疗 新英格兰:乳腺癌内分泌治疗耐药有救 ...
NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.NCCN Guidelines IndexNCCN Guidelines Version 1.2023Table of ContentsSquamous Cell Skin Cancer DiscussionNCCN Squamous Cell Skin Cancer Panel Members...